 This is a Phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety and immunogenicity of a 2-injection vaccine regimen with Chikungunya virus CHIKV and virus like particle vaccine CHIKV VLP in healthy adults. 